Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| ACAD | ACADIA PHARMACEUTICALS INC | 2025-10-16 18:42:11 | 20.51 | -0.11 | -0.53 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACAD | 0001070494 | ACADIA PHARMACEUTICALS INC | US0042251084 | 529900O3044NO0PEA039 | 061376651 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 12830 EL CAMINO REAL | SAN DIEGO | CA | 92130 | UNITED STATES | US | 858-558-2871 | 12830 EL CAMINO REAL, SAN DIEGO, CA, 92130 | 12830 EL CAMINO REAL, SAN DIEGO, CA, 92130 | — | Biopharmaceutical | 1993 | Stephen R. Davis | 570 | http://acadia.com | 2,000,000,000 | 168,607,881 | 168,712,220 | Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California. | 2025-10-10 20:22:25 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 2,000,000,000 | -900,000,000 | -31.0345 | 166,788,517 | 2,016,996 | 1.2241 |
| 2023 | 2,900,000,000 | 1,200,000,000 | 70.5882 | 164,771,521 | 2,541,337 | 1.5665 |
| 2022 | 1,700,000,000 | -800,000,000 | -32 | 162,230,184 | 1,026,436 | 0.6367 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 654 |
| 2023 | 598 |
| 2022 | 513 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 957,797,000 | 726,437,000 | 517,235,000 |
| Cost Of Revenue | 81,841,000 | 41,638,000 | 10,166,000 |
| Gross Profit | — | 684,799,000 | 507,068,000 |
| Research And Development Expenses | 303,249,000 | 351,619,000 | 361,575,000 |
| General And Administrative Expenses | 488,428,000 | 406,559,000 | 369,090,000 |
| Operating Expenses | 727,003,000 | 799,816,000 | 740,831,000 |
| Operating Income | 230,794,000 | -73,379,000 | -223,596,000 |
| Net Income | 226,451,000 | -61,286,000 | -215,975,000 |
| Earnings Per Share Basic | 1.37 | -0.37 | -1.34 |
| Earnings Per Share Diluted | 1.36 | -0.37 | -1.34 |
| Weighted Average Shares Outstanding Basic | 165,717,000 | 163,819 | 161,683 |
| Weighted Average Shares Outstanding Diluted | 166,362,000 | 163,819 | 161,683 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 319,589,000 | 188,657,000 | 114,846,000 |
| Marketable Securities Current | 436,404,000 | 250,208,000 | 301,977,000 |
| Accounts Receivable | 98,739,000 | 98,267,000 | 62,195,000 |
| Inventories | 91,690,000 | 40,447,000 | 11,560,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 55,681,000 | 39,091,000 | 21,398,000 |
| Total Assets Current | 938,318,000 | 616,125,000 | 507,937,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 4,215,000 | 4,612,000 | 6,021,000 |
| Other Assets Non Current | 359,000 | 476,000 | 7,587,000 |
| Total Assets Non Current | 249,438,000 | 132,831,000 | 79,875,000 |
| Total Assets | 1,187,756,000 | 748,956,000 | 587,812,000 |
| Accounts Payable | 16,192,000 | 17,543,000 | 12,746,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 378,678,000 | 236,711,000 | 112,884,000 |
| Total Liabilities Current | 394,870,000 | 254,254,000 | 125,630,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | 18,056,000 | 15,147,000 | 9,074,000 |
| Total Liabilities Non Current | 60,093,000 | 62,947,000 | 61,769,000 |
| Total Liabilities | 454,963,000 | 317,201,000 | 187,399,000 |
| Common Stock | 16,000 | 16,000 | 16,000 |
| Retained Earnings | -2,204,386,000 | -2,430,837,000 | -2,369,551,000 |
| Accumulated Other Comprehensive Income | 292,000 | 24,000 | -975,000 |
| Total Shareholders Equity | 732,793,000 | 431,755,000 | 400,413,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 920,000 | 1,459,000 | 2,026,000 |
| Share Based Compensation Expense | 67,049,000 | 66,421,000 | 68,201,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 472,000 | 36,072,000 | -2,171,000 |
| Change In Inventories | 49,550,000 | 28,808,000 | -2,415,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | -117,000 | 33,000 | 48,000 |
| Change In Accounts Payable | -1,351,000 | 4,797,000 | 5,870,000 |
| Change In Other Liabilities | 2,909,000 | 6,073,000 | 2,040,000 |
| Cash From Operating Activities | 157,719,000 | 16,702,000 | -114,035,000 |
| Purchases Of Marketable Securities | 505,095,000 | 369,985,000 | 363,174,000 |
| Sales Of Marketable Securities | 328,565,000 | 429,780,000 | 436,415,000 |
| Acquisition Of Property Plant And Equipment | 523,000 | 50,000 | 0 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -30,538,000 | 31,998,000 | 73,241,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 6,845,000 | 25,129,000 | 8,199,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 6,845,000 | 25,129,000 | 8,199,000 |
| Change In Cash | 133,932,000 | 73,811,000 | -32,589,000 |
| Cash At End Of Period | 319,589,000 | 188,657,000 | 114,846,000 |
| Income Taxes Paid | 19,521,000 | 5,850,000 | 2,190,000 |
| Interest Paid | — | — | — |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | 1.37 | -0.37 | -1.34 |
| Price To Earnings Ratio | 13.3942 | -84.6216 | -11.8806 |
| Earnings Growth Rate | -470.2703 | -72.3881 | — |
| Price Earnings To Growth Ratio | -0.0285 | 1.169 | — |
| Book Value Per Share | 4.422 | 2,635.5612 | 2,476.5312 |
| Price To Book Ratio | 4.1497 | 0.0119 | 0.0064 |
| Ebitda | 246,892,000 | -53,977,000 | -211,759,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 523,000 | 50,000 | 0 |
| Free Cash Flow | 157,196,000 | 16,652,000 | -114,035,000 |
| Return On Equity | 0.309 | -0.1419 | -0.5394 |
| One Year Beta | 0.7986 | 1.2241 | 1.0878 |
| Three Year Beta | 1.0593 | 0.949 | 0.8508 |
| Five Year Beta | 0.875 | 0.9047 | 1.0018 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | 2025-09-15 | 3,498 | D | 43,447 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | 2025-09-12 | 6,815 | A | 46,945 |
| GAROFALO ELIZABETH A. | Director | 2025-09-02 | 1,600 | D | 25,382 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | 2025-08-18 | 22,000 | D | 40,130 |
| Brege Laura | Director | 2025-06-04 | 14,446 | D | 15,095 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Christopher L. Jacobs | 2022-07-28 | NY27 | Sale | 2022-06-16 | — | $1,001 - $15,000 |
| Christopher L. Jacobs | 2020-11-06 | NY27 | Sale (Partial) | 2020-09-08 | — | $1,001 - $15,000 |
| Gilbert Cisneros | 2019-03-08 | CA39 | Sale | 2019-02-19 | — | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Lowe Wealth Advisors, LLC | 2025-09-30 | 3,841 | 180 | 21.3389 |
| RICE HALL JAMES & ASSOCIATES, LLC | 2025-09-30 | 13,122,756 | 614,937 | 21.34 |
| BURNEY CO/ | 2025-09-30 | 2,286,304 | 107,137 | 21.34 |
| Blue Trust, Inc. | 2025-09-30 | 299 | 14 | 21.3571 |
| CWM, LLC | 2025-09-30 | 794,000 | 37,223 | 21.3309 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| AMERICAN PENSION INVESTORS TRUST | 2025-07-31 | Institutional Class | YOVIX | 12,050 | 287,151.5 | 0.933 |
| AMERICAN PENSION INVESTORS TRUST | 2025-07-31 | Class L | YOVLX | 12,050 | 287,151.5 | 0.933 |
| AMERICAN PENSION INVESTORS TRUST | 2025-07-31 | Class A | YOVAX | 12,050 | 287,151.5 | 0.933 |
| ETFis Series Trust I | 2025-07-31 | Virtus LifeSci Biotech Products ETF | BBP | 20,441 | 487,109.03 | 1.9765 |
| Advisors' Inner Circle Fund III | 2025-07-31 | I Shares | KCXIX | 555 | 13,225.65 | 0.0054 |